Fusion Family Wealth’s Redhill Biopharma RDHL Stock Holding History

Fusion Family Wealth’s Portfolio RDHL Stock Details RDHL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-5	Closed	-$43K	–	287
2018 Q2	$43K	Buy	+5	New	+$31.8K	0.01%	135

Other funds holding RDHL

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Menta Capital San Francisco, California $236M AUM 6.6% 1-Year Est. Return

Fusion Family Wealth's RDHL Position: Q3 2018 in Review

Fusion Family Wealth sold out of Redhill Biopharma (RDHL) in Q3 2018, closing a stake of 5 shares — an estimated $43K sold.

Fusion Family Wealth first reported a position in RDHL in Q2 2018 and held it in 1 quarter. The position peaked at $43K in Q2 2018. 38 funds tracked by Wall St. Rank hold RDHL as of Q3 2018.

Fusion Family Wealth reported no remaining Redhill Biopharma position as of Q3 2018 after selling out during the quarter.
Fusion Family Wealth sold 5 Redhill Biopharma shares in Q3 2018, an estimated $43K.
Fusion Family Wealth first reported a position in Redhill Biopharma in Q2 2018 and held it in 1 quarter.
Fusion Family Wealth's Redhill Biopharma position peaked at $43K in Q2 2018.
38 funds tracked by Wall St. Rank held Redhill Biopharma as of Q3 2018.

Based on Fusion Family Wealth's 13F filing for Q3 2018, filed 7 Nov 2018.